Replies to post #246280 on Biotech Values

[marthambles]

I don't know the answer to your question, but Sentiv is a highly respected member of the twitter biotech community.

[dewophile]

I don't think companies would stop development in NASH even if this were the case - angling for combination therapy / sequential therapy w different MOA, having an alternative w different profile from adverse events, DDIs, etc. It''s not like say HCV where you had a cure rate of 95+% w super easy regimen where there is no room for improvement and you basically shut down all research in the field. But it would dampen things somewhat sure